Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

if government regulation is stricter for the Group's new products than for existing treatments; - if the new products suffer a loss of patent protection or competitors successfully challenge or circumvent the Group's patents or regulatory exclusivity; - if planned geographical expansion into emerging markets is not successful; or - if the size of the patient population for the new product is less than expected or the Group fails to identify new patients for the new products.

If the Group is unable to commercialize ELAPRASE, VYVANSE, LIALDA, FIRAZYR, FOSRENOL (ROW) or any of its new products successfully, there may be a material adverse effect on the Group's revenues, financial condition and results of operations.

Any decrease in the combined sales of VYVANSE and ADDERALL XR will significantly reduce revenues and earnings

In 2008, the combined sales of VYVANSE and ADDERALL XR were $1,420.6 million, representing approximately 47% of the Group's total revenues. Sales of ADDERALL XR are expected to decrease significantly due to generic competition that is anticipated to commence on April 1, 2009. Any factors that decrease the sales of ADDERALL XR more significantly than expected could have a material adverse effect on the Group's financial condition and results of operations. In addition, the entrance of generic competitors for ADDERALL XR or other leading attention deficit and hyperactivity disorder ('ADHD') medications could impact the sales of VYVANSE. Other factors that could impact the sales of VYVANSE or ADDERALL XR include, but are not limited to:

    - faster than anticipated erosion of ADDERALL XR sales by
      generic competitors;

    - the development and marketing of competitive pharmaceuticals to VYVANSE
      and ADDERALL XR;

    - issues impacting the production of VYVANSE or ADDERALL XR or the supply
      of 
'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... CA (PRWEB) July 30, 2014 ... presentations of leading Immunologists, Principle Investigators, scientists in ... Charles J Malemud, Professor at Case Western Reserve ... delivering his keynote address on “The effects ... in production of matrix metalloproteinase-9”. Arya Biragyn, a ...
(Date:7/29/2014)... 30, 2014 “PharmaSphere: Emerging Biotech ... Venture Capital Funding” report provides in-depth analysis of ... equity and venture capital segments of the financial ... to have significant impact on the future of ... Furthermore, the report identifies regions of the world ...
(Date:7/29/2014)... DIEGO , July 29, 2014   Sequenom, ... sciences company that provides innovative genetic analysis solutions, and ... of esoteric laboratory services in the United ... noninvasive prenatal testing patents and applications. "We ... innovation, and patient care, and we welcome the opportunity ...
(Date:7/29/2014)... (July 29, 2014) Tough, ultralight foam of atom-thick ... through a chemical process invented at Rice University. ... like a nanoscale building, with floors and walls that ... of two-dimensional materials: floors and walls of graphene oxide ... platelets. , The researchers say the foam could ...
Breaking Biology Technology:Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4Tough foam from tiny sheets 2
... Texas , May 13 U.S. Renal Care, Inc. ... that it is extending its previously announced cash tender offer, through ... shares of common stock of Dialysis Corporation of America (Nasdaq: ... City time, on June 1, 2010 , unless further ...
... , May 13 /PRNewswire-Asia/ -- A signing ceremony for ... (TJAB) and Genzyme Corporation was held in the,Tianjin Economic-Technological Development Area ... , , ... Zihe, President of TJAB and,President of Nankai University, He Shushan, Director ...
... Texas , May 13 Sergio Lopez , 18, of ... marrow-derived stem cells in lieu of traditional surgery to repair a broken bone ... as a non-union, is to implant a device, such as a screw or ... , , ...
Cached Biology Technology:U.S. Renal Care, Inc. Announces Extension of Tender Offer for Dialysis Corporation of America 2U.S. Renal Care, Inc. Announces Extension of Tender Offer for Dialysis Corporation of America 3Tianjin International Joint Academy of Biotechnology and Medicine, Genzyme Enter into Strategic Partnership 2Texas Teen Opts for Stem Cell Therapy, Hopes of Enlisting in Military 2Texas Teen Opts for Stem Cell Therapy, Hopes of Enlisting in Military 3
(Date:7/30/2014)... figured out how to create colors, nature had already ... of many different hues, for example. Now scientists are ... friendly way to make colored plastics. Their paper on ... materials rather than dyes, to produce color appears ... N. Asger Mortensen, Anders Kristensen and colleagues point out ...
(Date:7/30/2014)... of Engineering recently received a $330,000 award from ... synthesis of organic nanorods." , According to ... and utilization of functional materials, devices, and systems ... in scaling up nanotechnology is the lack of ... one device. A research team led by Dr. ...
(Date:7/30/2014)... spinal cord injury (SCI), traumatic brain injury (TBI) and ... has been learned over the past 30 years regarding ... regulate axon growth, but this large body of information ... Lemmon and his team from University of Miami in ... but a consensus is emerging that one contributing factor ...
Breaking Biology News(10 mins):NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... YORK, N.Y. Cornell University and the United Nations University ... health, governance and security of the African continent when it ... Nov. 13. The series is free and open to the ... will be Africas food system and its interactions with health ...
... Hospital of Pittsburgh of UPMC are participating in an international ... insulin in preventing or delaying the onset of type 1 ... researchers want to determine if one insulin capsule taken daily ... in relatives of people who are found to be at ...
... Human Genome Sciences, Inc. (Nasdaq: HGSI) today ... demonstrating that LymphoStat-B (belimumab) achieved a sustained improvement ... the frequency of disease flares over time, and ... in combination with standard of care in patients ...
Cached Biology News:First symposium of UN University-Cornell Africa Series to be held at UN 2Children's Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes 2HGS announces positive Phase 2 LymphoStat-B at ACR meeting 2HGS announces positive Phase 2 LymphoStat-B at ACR meeting 3HGS announces positive Phase 2 LymphoStat-B at ACR meeting 4
... reagent has been developed for use ... reduction of nonspecific background staining due ... describe blocking peroxidase with hydrogen peroxide. ... in combination with additional novel components ...
Rabbit polyclonal to Wilms Tumor Protein ( Abpromise for all tested applications). entrezGeneID: 7490 SwissProtID: P19544...
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Request Info...
Biology Products: